Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in Replimune Group, Inc. (NASDAQ:REPL) by 0.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,429,666 shares of the company’s stock after acquiring an additional 1,365 shares during the period. Geode Capital Management LLC owned 2.09% of Replimune Group worth $17,318,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in REPL. State Street Corp raised its holdings in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Barclays PLC raised its stake in shares of Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after buying an additional 98,791 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Replimune Group by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 249,349 shares of the company’s stock valued at $2,733,000 after buying an additional 8,074 shares during the period. SG Americas Securities LLC boosted its stake in Replimune Group by 14.7% during the fourth quarter. SG Americas Securities LLC now owns 26,291 shares of the company’s stock valued at $318,000 after buying an additional 3,374 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Replimune Group by 24.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company’s stock worth $198,000 after acquiring an additional 3,177 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Stock Up 4.7 %

NASDAQ:REPL opened at $7.99 on Friday. The business’s fifty day moving average price is $10.75 and its 200 day moving average price is $11.75. The firm has a market capitalization of $615.35 million, a price-to-earnings ratio of -2.60 and a beta of 1.26. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

REPL has been the subject of several research reports. BMO Capital Markets raised their price objective on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. increased their price objective on Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, HC Wainwright lifted their target price on Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $19.43.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.